RESEARCH ARTICLE

Moderate Increase of Indoxyl Sulfate Promotes Monocyte Transition into Profibrotic Macrophages

Chiara Barisione1*, Silvano Garibaldi1, Anna Lisa Furfaro2, Mariapaola Nitti3, Daniela Palmieri4, Mario Passalacqua3, Anna Garuti5, Daniela Verzola6, Alessia Parodi7, Pietro Ameri1, Paola Altieri1, Patrizia Fabbi1, Pier Francesco Ferrari8, Claudio Brunelli1, Violeta Arsenescu9, Manrico Balbi1, Domenico Palombo4, Giorgio Ghigliotti1

1 Division of Cardiology, IRCCS University Hospital San Martino, Research Centre of Cardiovascular Biology, University of Genova, Genova, Italy, 2 Giannina Gaslini Institute, Genova, Italy, 3 Department of Experimental Medicine, University of Genova, Genova, Italy, 4 Unit of Vascular and Endovascular Surgery, University of Genova, Genova, Italy, 5 Department of Internal Medicine, IRCCS University Hospital San Martino, University of Genova, Genova, Italy, 6 Nephrology Division, Department of Internal Medicine, IRCCS University Hospital San Martino, University of Genova, Genova, Italy, 7 Centre of Excellence for Biomedical Research (CEBR), University of Genova, Genova, Italy, 8 Department of Civil, Chemical and Environmental Engineering, University of Genoa, Genoa, Italy, 9 Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University, Columbus, OH, United States of America

* chiara.barisione@unige.it

Abstract

Objective

The uremic toxin Indoxyl-3-sulphate (IS), a ligand of Aryl hydrocarbon Receptor (AhR), raises in blood during early renal dysfunction as a consequence of tubular damage, which may be present even when eGFR is normal or only moderately reduced, and promotes cardiovascular damage and monocyte-macrophage activation. We previously found that patients with abdominal aortic aneurysms (AAAs) have higher CD14+CD16+ monocyte frequency and prevalence of moderate chronic kidney disease (CKD) than age-matched control subjects. Here we aimed to evaluate the IS levels in plasma from AAA patients and to investigate in vitro the effects of IS concentrations corresponding to mild-to-moderate CKD on monocyte polarization and macrophage differentiation.

Methods

Free IS plasma levels, monocyte subsets and laboratory parameters were evaluated on blood from AAA patients and eGFR-matched controls. THP-1 monocytes, treated with IS 1, 10, 20 μM were evaluated for CD163 expression, AhR signaling and then induced to differentiate into macrophages by PMA. Their phenotype was evaluated both at the stage of semi-differentiated and fully differentiated macrophages. AAA and control sera were similarly used to treat THP-1 monocytes and the resulting macrophage phenotype was analyzed.

Results

IS plasma concentration correlated positively with CD14+CD16+ monocytes and was increased in AAA patients. In THP-1 cells, IS promoted CD163 expression and transition to...
macrophages with hallmarks of classical (IL-6, CCL2, COX2) and alternative phenotype (IL-10, PPARγ, TGF-β, TIMP-1), via AhR/Nrf2 activation. Analogously, AAA sera induced differentiation of macrophages with enhanced IL-6, MCP1, TGF-β, PPARγ and TIMP-1 expression.

**Conclusion**
IS skews monocyte differentiation toward low-inflammatory, profibrotic macrophages and may contribute to sustain chronic inflammation and maladaptive vascular remodeling.

**Introduction**
Renal and cardiovascular (CV) damage often coexist with mutual detrimental feedback. While the presence of advanced chronic kidney disease (CKD) is an established risk factor for increased CV morbidity and mortality [1], the cardiovascular burden attributable to mild CKD is still underestimated and only partially characterized.

More recent is the assumption that renal function, traditionally evaluated by monitoring the estimated glomerular filtration rate (eGFR), may be assessed and refined with circulating and urinary biomarkers of tubular damage, because these markers are more sensitive and specific than serum creatinine to early changes in renal function, retain predictive value and confer independent excess risk for clinical outcomes as was shown in in patients with heart failure (HF) [2].

Early during CKD progression, protein-bound compounds, normally cleared by healthy kidneys, accumulate in blood and tissue. They are referred to as uremic toxins (UT) and exert noxious effects on different cell types and organs, including the CV system.

One of the best studied UT is the organic anion indoxyl-3-sulfate (IS). In physiological conditions, the circulating IS is cleared by renal proximal tubular secretion. In contrast, the total amount of IS rises up to 500 μM and beyond in blood of uremic patients as a consequence of tubular renal damage [3]. High IS concentrations participate in the development of both CKD and CV disease (CVD) [4–6].

IS is an agonist of the Aryl-hydrocarbon receptor (AhR), a ligand-activated transcription factor involved in the regulation of many biological functions [7,8,9]. In particular, AhR is overexpressed during monocyte-to-macrophage transition; AhR signaling cross-talks with the NF-E2p45-related factor 2 (Nrf2)-Heme Oxygenase-1 (HO1) pathway, which mediates antioxidant responses [10], and with the nuclear receptor Proliferator-Activated Receptor gamma (PPARγ) [11,12], which has anti-inflammatory activity and is upregulated during macrophage differentiation [13].

High IS levels, as found in end-stage CKD, have also been shown to affect monocyte/macrophage activation [14,15]. Remarkably, monocyte activation is implicated in the pathogenesis of abdominal aortic aneurysm (AAA) [16,17].

We recently reported that patients with AAA frequently have mild-to-moderate CKD and an expanded population of CD14⁺CD16⁻ monocytes [18], which represent an intermediate subset among the ‘classical’ (CD14⁺CD16⁻) and ‘nonclassical’ (CD14dimCD16⁺) ones. Monocytes also express various scavenger receptors, including the membrane haemoglobin-haptoglobin complex, CD163, which identifies a pool of monocytes more resistant to oxidative stress [19]. In this paper, we initially measured IS levels in sera from AAA patients and eGFR matched control subjects and analyzed their relationship with markers of inflammation and monocyte subpopulations. Next, we characterized how IS at the concentrations found in early stages of CKD, which is the condition observed in our AAA patients, impact on THP-1
monocyte/macrophage differentiation; finally, as proof of concept that circulating factors associated with AAAs modulate monocyte activation, the effects of IS and AAA sera on macrophage phenotypes were compared.

**Material and Methods**

**Study population**

This study was approved by the Ethics Committee of the University of Genoa, Italy, and adhered to the Declaration of Helsinki Principles. We studied 45 patients undergoing elective open repair of AAA, recruited at the Unit of Vascular and Endovascular Surgery of the San Martino-IST hospital (Genoa, Italy) and 19 age-matched control subjects recruited from our outpatient clinic. All study participants, selected on the basis of the criteria listed in Table A in S1 File, gave their informed consent.

**Laboratory assessment**

Complete blood count and biochemical parameters were measured by means of standard techniques at the Laboratory Unit of the San Martino-IST Hospital. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the Glomerular Filtration Rate (eGFR) [20] and to categorize CKD stage as indicated in Table A in S1 File. Peripheral blood was centrifuged at 1710g for 15 minutes at 4°C and stored at -80°C for subsequent assessment. Free IS was measured on plasma samples (Human Indoxyl Sulfate ELISA Kit, MyBioSource, Inc. San Diego, CA USA).

**Human monocyte phenotyping**

Ficoll-isolated peripheral blood mononuclear cells (PBMCs) were immunostained with anti-CD14 PE (clone RMO52; Beckman Coulter), and anti-CD16 PECy5 (clone 3G8; Biolegend) antibodies. Monocytes were analysed by flow-cytometry (FACS calibur and CellQuest software from Becton Dickinson). The CD14⁺CD16⁻, CD14⁺CD16⁺ and CD14⁻CD16⁺ subsets were identified as previously described [21].

The surface CD163 expression was detected with the anti-human CD163 FITC-conjugate (clone GHI/61, Abcam); the intracellular AhR expression, was determined on cells permeabilized with Fix-Perm (BD) by unconjugated anti-AhR antibody (clone RPT9, Abcam) labeled with the green probe of Zenon Tricolor Mouse IgG1 Labeling Kit (Life technologies).

**Cell culture**

Monocyte THP-1 cell line was obtained from the European Collection of Cell Cultures (ECACC) and maintained in complete culture medium (RPMI, 10% FBS, 2% Glutamine and 1% Penicillin/Streptomycin). Cells were treated with 1, 10, 20 μM IS, that reflect mean IS values found in humans with stage I, II and III CKD [22], diluted in ultrapure H₂O. To hamper the AhR activation, cells were treated with 10 μM CH-223191 (CH), a selective AhR antagonist (Figure A in S2 File), diluted in DMSO, according to the manufacturer’s instruction (Sigma) and compared at different time points, on the basis of the experimental purposes. Cells were also incubated in medium containing sera pooled from the two study populations, indicated as AAA sera and Normal sera respectively (RPMI, 5% sera pooled from AAA patients or, alternatively, from control subjects, 2% Glutamine and 1% Penicillin/Streptomycin).

After treatment, THP-1 cells were induced to differentiate into macrophages by incubation in complete medium with 50 nM phorbol-myristate-acetate (PMA, Sigma) for 12 h; cells were
then washed with PBS and kept in complete medium for further 3 (semi-differentiated macrophages M/2M), or 6 days (monocyte-derived macrophages, MdM).

**Apoptosis and proliferation**

Apoptosis and proliferation were evaluated by flow cytometry (FACSCanto II, BD Italia, Facs-Diva software, BD) using Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit (Life Technologies) and carboxyfluorescein succinimidyl ester (CFDA-SE; Invitrogen, Milan, Italy) as previously described [23], respectively. The Proliferation Wizard module of the ModFit LT 3.2 software (Verity Software House, Topsham, ME, USA) was used and the results were expressed as percentage of cells in the first and second generation.

**Expression of CD163 and CCR2**

CD163 and CCR2 membrane expression was evaluated as median of cell fluorescence after staining with anti-human CD163 FITC-conjugate (clone GHI/61, Abcam) and the anti-human CCR2 Alexa Fluor 647 (clone 48607, Pharmingen). Cells were analyzed with FACS Calibur, software Cell Quest, and FACSCanto II, software FACSDiva, respectively (BD, Italy).

**ROS production**

Intracellular ROS production was evaluated by the CellROX® deep red kit from Life Technologies. Following treatments, CellROX® Reagent was added for 30 minutes, then cells were directly analyzed on FACSCanto II.

**Chemotaxis**

Migration assay was performed in Boyden chambers through polycarbonate polystyrene-free filters (5-nm pore size, Millipore). Five×10⁵ cells were placed in the upper compartment of the Boyden chamber and CCL2 (10 ng/ml) or PBS as negative control were placed in the lower compartment. Cells were incubated at 37°C for 3 hours. The migrated cells on the lower side of filters were fixed in ethanol, stained with toluidine blue (2%), and quantitated microscopically at a 20x magnification. Five random fields were counted.

**Confocal microscopy**

Cells fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, saturated with 0.5% serum albumin in PBS and incubated overnight at 4°C with the following primary antibodies: mouse monoclonal anti-AhR and rabbit polyclonal anti-AhRR (Abcam, UK). Chicken anti-rabbit Alexa Fluor 633 or chicken anti-mouse Alexa Fluor 488 labelled were used as secondary antibodies. Nuclei were counterstained with Propidium Iodide.

Images were collected by a three-channel TCS SP2 laser scanning confocal microscope (Leica Wetzlar, Germany). Co-localization was analyzed through two-dimensional correlation cytofluorograms accomplished by macro routines integrated as plugins in ImageJ 1.4 software (Wayne Rasband, NIH, Bethesda, MD, USA).

**cDNA reverse transcription and quantitative reverse transcription-PCR**

Total RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer’s instructions. RNA (1 μg) was reverse-transcribed into cDNA by random hexamer primer and SuperScript II Reverse Transcriptase (Invitrogen). Gene expression for NFE2L2 (Nrf2), HMOX1 (HO1), AhR, AhRR and RPLP0 were performed with pre-designed primers Prime-Time Mini qPCR Assay by IDT TemaRicerca (Italy), using the TaqMan Universal PCR Master
Mix on a 7900HT Fast Real Time PCR System (Applied Biosystems). Results were normalized to RPLP0 expression. Gene expression for CCR2, IL-6 and CCL2 was quantified using β-Actin for the normalization. The corresponding primers were obtained from Primerdesign (Southampton, UK). PCR amplification was carried out using the SYBR Green solution Mastermix on a Master Cycler Real Plex PCR system (Eppendorf, Hamburg, Germany) (Table B in S1 File). Assays were run in triplicate. The 2-ΔΔCT method of relative quantification was used to determine the mRNA fold induction in IS-treated versus Control cells.

**Western blotting**

Cell were lysated in RIPA buffer and run on reducing SDS-acrylamide gels. Samples were electrotransferred to PVDF, and the membranes were saturated at room temperature for 1 h, incubated with primary antibodies overnight, and then with the corresponding horseradish peroxidase-secondary antibodies (Santa Cruz) for 1 h at room temperature. The bands were visualized by ECL chemiluminescence (Pierce). The membranes were stripped (20 min at 50°C) and re-blotted with GAPDH antibody. Bands were quantified by optical densitometry (gel analysis system GeneGenius, Syngene, Cambridge, UK). Primary antibodies: mouse-monoclonal anti-AhR (RPT9), rabbit- polyclonal AhRR, rabbit-polyclonal anti-PPARγ, mouse monoclonal anti HO1 from Abcam; rabbit polyclonal anti-TGF-β from Cell Signaling; rabbit polyclonal anti TIMP-1 from Chemicon; rabbit polyclonal GAPDH, rabbit polyclonal anti-Nrf2, rabbit polyclonal anticytochrome P450-reductase (CYPOR) and rabbit polyclonal anti-COX2 from Santa Cruz.

**Zymography for MMP-9**

Equivalent protein amounts from culture medium were loaded on SDS acrylamide gel cast with 0.28% w/v gelatine (type A), run at 6–8°C in a water-cooled box, rinsed twice for 30 min, incubated for 16–18h at 37°C with incubation buffer, stained and destained with the relative buffers. Uncolored bands were quantified by optical densitometry (gel analysis system GeneGenius, Syngene, Cambridge, UK).

**CCL2 and IL-10 quantification**

IL-10 and CCL2 levels were measured in culture medium by Instant ELISA immunoassay according to manufacturer instructions (BMS215INSTCE and MS281INSTCE, eBioscience).

**Buffer Recipes**

See Buffer Recipes in S1 File.

**Statistical analysis**

Continuous clinical and laboratory parameters are presented as mean±SD or median (interquartile range) depending on their normal or skewed distribution. Comparisons were drawn by t-test, Mann-Whitney test, Chi-square test as appropriate. The relationship between IS concentrations and selected variables was examined by means of the Pearson (for normally distributed data) or Spearman (for skewed data distributions) correlation test. In vitro experiments were performed at least 3 times; data are given as mean ± SEM and were compared by Student’s t test and ANOVA. Statistical significance was set at p<0.05. All statistical analyses were performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, California, USA.
Results
Levels of free IS and correlation with eGFR and monocyte subsets in blood of AAA patients and Control subjects

Since IS accumulates in the blood during early renal dysfunction, both as albumin-bound and free fraction, we compared the concentrations of free IS, which is the biologically active form, between AAA patients and control subjects selected for having a similar eGFR (74.95± 2.35 vs. 73.73±2.9, mean ±SEM; p = NS). When compared to control subjects, AAA patients had significantly higher levels of free IS (18.5±0.62 nM vs. 14.43±1.39 nM, mean±SEM; p = 0.004) (Fig 1A; Table C in S1 File) and of D-dimer [18] (Table D in S1 File).

In the total study population, IS correlated positively with the percentage of circulating CD14+CD16+ monocytes (p = 0.015, r = 0.3) (Fig 1B) and negatively with eGFR (0.039) (Table E in S1 File). Interestingly, when separately considering AAA patients and control subjects, IS was inversely related to eGFR only in control subjects (p = 0.02, r = -0.5425), while there was no association in AAA patients (Fig 1C and 1D).

AhR was more expressed in CD16+ monocytes than in CD16- monocytes, the highest levels being in CD14+CD16+ monocytes (Figure B-A in S2 File). Consistent with previous reports [24], also CD163 was maximally expressed by CD14+CD16+ monocytes, while its levels were
lower in CD14^+CD16^- cells and barely detectable in the CD14^{dim}CD16^- subset (Figure B-B in S2 File).

**AhR-dependent effect of IS on CD163 expression in THP-1 monocytes**

IS upregulated CD163 expression in a concentration- and time-dependent manner: after 48 hours, 1, 10, and 20 μM IS induced, respectively, a 1.5, 2.5 and 2.8-fold increase in CD163 versus control; after 72 hours, CD163 levels were increased 2.3, 2.5 and 2.9 times respectively versus control (Fig 2A). CD163 induction was counteracted by the AhR antagonist CH, confirming that IS effect was AhR-mediated (Fig 2A).

**Effects of IS on THP-1 monocyte viability, ROS production, and proliferation**

Cell incubation with IS ± the AhR-antagonist CH did not significantly change the apoptotic rate compared to control cells (Figure C-A in S2 File). Cell incubation with 1, 10, 20 μM IS transiently increased the ROS production at 30 minutes (respectively 268 ± 18%, 177 ± 26%, 239 ± 36%, vs. untreated cells, p<0.05), although values were significantly lower than those obtained after exposure to 1 mM IS (464± 31% vs. untreated cells, p<0.001) which corresponds to the maximal uremic concentration [3] and was used as positive control. After 45 minutes, only 1 mM IS treated cells displayed an increased ROS production compared to control cells (p<0.001). No significant differences between IS-treated and control cells were observed at longer incubation times (Figure C-B in S2 File). Treatment with IS for 72 hours significantly reduced cell proliferation, as revealed by the percentage of cells in the second generation. In contrast, pre-treatment with CH dramatically increased the proliferation rate compared to control cells (Fig 2B).

**IS induces CCL2 dependent migration of THP-1 monocytes**

Cells treated for 48 h with IS were allowed to migrate toward a CCL2 gradient in a Boyden chamber for 3 h. Chemotaxis induced by CCL2 was increased after treatment with 20 μM IS and effectively counteracted by pre-treatment with CH (Fig 2C).

The increased migratory rate was not attributable to an enhanced expression of the CCL2 receptor CCR2, since its membrane expression was not affected by IS/CH treatment (Fig 2D). Rather, we found that CCR2 was significantly down regulated as gene expression after a 10 and 20 μM IS treatment (Fig 2E). Therefore, we believe that IS-induced migratory activity could be ascribed to a cell commitment in monocyte-to-macrophage transition, as confirmed by the dramatic increase in CCL2 transcript levels (Fig 2F), a phenomenon already described [25].

**AhR/AhRR ratio in IS-treated THP-1 monocytes**

The cell responses induced by ligand-activated AhR are counteracted by the AhR Repressor (AhRR), which translocates to the nucleus and inhibits AhR. This feedback loop was maintained in THP-1 monocytes exposed to IS: indeed, IS treatment for 72 hours increased the nuclear localization of both AhR and AhRR in a concentration-dependent manner (Fig 2G). AhRR dampens AhR-dependent activation of xenobiotic metabolizing enzymes such as cytochrome p450. We evaluated the net activity resulting from the ratio AhR/AhRR by considering the protein expression of cytochrome p450 reductase (CYPOR), an electron donor that is a substrate for cytochrome p450. CYPOR was decreased in 10 and 20 μM IS treated cells (37 ± 16 and 47 ± 25% respectively), indicating that the cells are in a metabolic stressed status (Fig 2H).
**Fig 2. Effects of IS on THP-1 monocytes.** Effect of 72 h treatment with 1, 10, 20 μM IS ±10 μM CH-223191 pretreatment (dashed bars) on (A) CD163 expression; § p < 0.05; **p < 0.01 vs. CTR; ***p < 0.001 vs. CTR; (B) Proliferation rate expressed as % of cells in first (grey bars) and second (white bars) generation as evaluated by flow cytometry using the CFSE-DA probe; *p < 0.05 vs. IS1; **p < 0.01 vs. CTR; #p < 0.01 vs. the corresponding IS alone.
Effects of IS on the macrophage differentiation of THP-1 cells

THP-1 cells treated with IS for 72 h were stimulated with PMA to differentiate into macrophages. IS-primed M/2M macrophages displayed an upregulation of the AhR/Nrf2 pathways: the gene expression was modestly enhanced for AhR (30% and 60% in M/2M treated, respectively, with 10 μM and 20 μM IS vs. control), AhRR (about 50% increase at the three concentrations vs. control), Nrf2 (about a 50% increase vs control with 10 and 20 μM IS) and HO-1 (a 50% increase vs control for 10 and 20 μM IS) (Fig 3A–3D). AhR activation leads to overexpression of inflammatory cytokines such as IL-6 and CCL2 [26,27]. In our conditions, the IL-6 concentrations; (C) Chemotaxis during 3 hours of incubation in a Boyden chamber after a 48 h IS treatment; CCL2 (10 ng/ml) and PBS were used as chemoattractant and negative control respectively. Values are expressed by means of cell number/field on a polycarbonate polyvinylpyrrolidone-free filter (5-nm pore size). *p<0.05; § p<0.05; #p<0.05 vs 20μM IS. (D) CCR2 membrane expression in cells after 72 h IS treatment evaluated by flow cytometry. (E) CCR2 and (F) CCL2 gene expression in cells after 24 h IS treatment as revealed by RT-PCR; **p<0.01; ***p<0.001 vs. CTR. Results are plotted as mRNA fold induction (mean ± SEM) versus control cells. (G) Immunofluorescence localization of AhR (green) and AhRR (blue) after a 72 hour IS treatment; nuclei are counterstained with Propidium Iodide (red). (H) Protein expression of CYPOR (cytochrome p450 reductase); * p <0.05; *** p <0.01 vs. CTR.
gene expression was increased in 10 and 20 μM IS-treated M/2M macrophages, with the highest levels observed in 10 μM IS-treated cells (Fig 3E). Similarly, CCL2 RNA transcript was dramatically upregulated in 10 and 20 μM IS-treated M/2M macrophages (Fig 3F).

Monocyte-derived-macrophages (MdM) were obtained after further 3 days of incubation. Compared to control MdM, 10 and 20 μM IS-primed-MdM exhibited higher AhR and AhRR expression (Fig 4A and 4B). Accordingly, CYPOR was down-regulated by IS treatment (Fig 4C). Of the Nfr2/HO1/PPARγ signaling pathway, only the expression of latter was upregulated by IS (Fig 4D–4F). Other two fibrogenic mediators, TGF-β and TIMP-1, were up-regulated by IS (Fig 4G and 4H). Furthermore, IS primed MdM had a reduced activity of MMP-9 and an enhanced secretion of IL-10 (Fig 4I and 4J). On the other hand, IS increased the CCL2 release and the protein expression of COX2, a marker of proinflammatory macrophage differentiation (Fig 4K and 4L).

Effects of Sera from AAA patients and control subjects on macrophage differentiation of THP-1 cells

THP-1 cells were stimulated with PMA to differentiate into macrophages after a 72 hour incubation in medium containing sera pooled from the 2 study groups. AAA sera, compared to control-sera, dramatically enhanced the gene expression of IL-6 (p = 0.0016) and CCL2 (p = 0.0025) in M/2M (Fig 5A and 5B). In MdM, AAA sera increased PPARγ, TGF-β and TIMP-1 total proteins, consistent with a profibrotic immune response, while reduced the CYPOR expression (Fig 5C–5F).

Discussion

The main finding of our study is that a moderate increase of IS, as found during transition from mild to moderate kidney damage, promotes monocyte differentiation towards macrophages with low-inflammatory, profibrotic potential.

We also demonstrated that free IS, the biologically active fraction, is higher in AAA patients than control subjects matched for age and eGFR levels, correlates with the percentage of the CD14+CD16+ monocyte subset, whose frequency is increased in CKD [28] and other chronic inflammatory diseases, including AAA [18]. CD14+CD16+ monocytes have a proinflammatory, senescent phenotype [29], differentiate into tissue macrophages and have the highest expression of CD163. CD163 participates to the Nrf2-HO1 signaling [30,31] and, by modulating HO1 expression, is indirectly linked to IL-10 production [32].

IS is one of the most investigated UT for its negative impact on the CV system. Clinical studies have demonstrated that IS serum levels are a powerful predictor of overall and cardiovascular mortality [33].

IS at uremic concentration (100–500 μM) exerts multiple detrimental and proinflammatory effects. To name a few, IS induces fibrosis in renal tubular cells, mesangial cells and aortic smooth muscle cells; IS also increases the macrophage responsiveness to LPS and the activation of monocytes through a ROS-production mediated mechanism [34,14], Nrf2 downregulation [35] and induces tissue factor expression in monocytes and endothelial cells [15].

IS is a potent AhR ligand [36]. Alteration of the AhR signaling plays a causative role in chronic inflammatory conditions [37,38]; the equilibrium between AhR and its repressor (AhRR), rather than the induction of AhR expression, establishes the AhR contribution to cell responses [39].

In our experimental conditions, we showed that IS activates the AhR/AhRR and Nrf2/HO1 pathways and arrests cell proliferation, an event associated to monocyte/macrophage transition [40]. IS treated THP-1 monocytes have increased CD163 expression and accelerated
Fig 4. Protein expression in IS treated MDM. Western Blot analysis of total cell lysates for (A) AhR, (B) AhRR, (C) CYPOR, (D) Nrf2, (E) HO1, (F) PPARγ, (G) TGF-β, (H) TIMP-1, (I) COX2; values are normalized to GAPDH expression. (J) Gelatinolytic activity of MMP-9. (K) IL-10 and (L) CCL2 content in IS-treated MDM conditioned medium. * p <0.05; ** p <0.01; *** p <0.001 vs. CTR.
Fig 5. Gene and protein expression in M/2M and MdM treated with sera from AAA patients and control subjects. RT-PCR for (A) IL-6, and (B) CCL2 in M/2M; results were plotted as mRNA fold induction in cell treated with AAA sera vs. cells treated with Normal sera. Western Blot analysis of total cell lysates for (C) PPARγ, (D) TGF-β, (E) TIMP-1, and (F) CYPOR.
chemotaxis toward a gradient of CCL2, a redox-dependent phenomenon reported in metabolically stressed monocytes [41]. These effects indicate a priming toward an alternative phenotype [42] which is counteracted by the AhR antagonist CH.

Upon PMA stimulation, IS primed THP-1 monocytes differentiate into macrophages with upregulated activation of AhR and features of both alternative (reduction of MMP-9 activity, overexpression of PPARγ, TIMP-1, TGF-β and IL-10) and classical (increased production of IL-6, CCL2 and COX2) immune response (Fig 6).

We believe that PPARγ activation may be responsible for the reduced transcription of inflammatory response genes, the upregulation of CD163 [43] and the modulation of the M1/M2 macrophage transition [44].

On the contrary, increased COX2 expression is considered at large as a marker of classical immune polarization. However, during inflammatory resolution, COX2 has been found to be upregulated even in IL-10-producing macrophages [45]. These observations remind us how macrophages retain various phenotypes associated to different inflammatory conditions.

So far, the presence of a mixed immune response, which is M2-like by surface marker expression but competent to produce extensive amounts of inflammatory cytokines, has been reported to be tissue- or site-specific, as observed for M2 macrophages infiltrating adipose tissue in obesity [46], for macrophages in the intestinal lamina propria [47] and in animal model of lung-specific IL-10 overexpression [48].

In this work, the highest levels of IL-6, CCL2 gene expression and IL-10 release and the lowest transcript levels of CCR2, which reflects monocyte maturation [25], have been observed after treatment with IS at concentrations found in subjects with moderate renal dysfunction.

The clinical relevance of this work may reside on the novel characterization of patients’ populations at increased risk for major CV events and having mild to moderate renal dysfunction. Indeed, eGFR was not different between AAA patients and control subjects, while the two study groups differ for IS levels. Furthermore, eGFR did not contribute and did not predict IS levels within the AAA subgroup of study patients. There may be several explanations for these findings. AAA patients have a high prevalence of renal artery stenosis [49] that promotes hypoxic tubular damage and makes the kidneys of these patients more vulnerable to hemodynamic changes and to ischemic and neurohormonal damage. Local and circulating proinflammatory milieu associated to AAA may trigger tubular damage and lead to impaired tubular cell function [50,51].

Chronic renal hypoxia associated to stenosis may also link tubular damage to interstitial fibrosis and inflammation. AAA patients frequently undergo repeated use of nephrotoxic contrast agents for computed tomography/magnetic resonance techniques [52].

To our knowledge this study is the first to evidence that free IS at levels found in subclinical renal dysfunction induce the differentiation of profibrotic macrophages. This process, by triggering a feed-forward system of vascular cell activation upon local release of CCL2 and TGF-β, may contribute to chronic inflammation and vascular remodeling [53].

In the clinical setting of patients with advanced AAA, increased IS levels may represent a mechanism that promotes recruitment of profibrotic macrophages into the aortic wall and other vessel districts, according to the homing sites of primed monocytes. Future studies should address the clinical applicability of strategies to reduce circulating IS levels to hamper arterial wall degeneration and organ damage.
Limitation of the study

Monocyte cell lines might not fully reflect the behavior of human monocytes. However, multiple pathways (i.e., AhR, Nrf2, PPARγ) of IS activity may be already primed in monocytes from healthy donors by, for instance, smoking habit [13], affecting the final response. Therefore, to avoid the confounding effects of the inter-donors variability, we performed the in vitro study using THP-1 and RAW 264.7 cells.

Concentrations of total IS are highly different from the concentrations of free plasma IS fraction, and the proportion between total IS and its free active form may vary for several reasons [3,54]. Thus, in the experimental plan we used the average values of total IS plasma levels found in mild-to-moderate CKD, the condition of our study subjects, as reported in literature.

Supporting Information

S1 File.
(DOC)

S2 File.
(PPTX)
Author Contributions
Conceived and designed the experiments: C. Barisione SG MN GG. Performed the experiments: C. Barisione SG MN D. Palmieri MP AG DV AP P. Altieri PFF. Analyzed the data: C. Barisione SG MP AG DV AP P. Altieri PF PFF MB D. Palombo GG. Contributed reagents/materials/analysis tools: MN D. Palmieri MP AG DV AP PFF C. Brunelli D. Palombo GG. Wrote the paper: C. Barisione SG MN P. Ameri VA MB GG.

References
1. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402–1407. PMID: 12234312
2. Damman K, Masson S, Hillege HL, Maggioni AP, Voors AA, Opasich C, et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 2011; 32:2705–2712. doi:10.1093/eurheartj/ehr190 PMID: 2166249
3. Vanholder R, De Smet R, Glorieux G, Argilés A, Baumeister U, Brunet P, et al. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934–1943. PMID:12675874
4. Barisione C, Ghigliotti G, Canepa M, Balbi M, Brunelli C, Ameri P. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets 2015; 16:366–72. PMID:25537654
5. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31:1771–9. doi:10.1093/eurheartj/ehp574 PMID: 20047993
6. Tang WH, Wang CP, Chung FM, Huang LL, Yu TH, Hung WC, et al. Uremic retention solute indoxyl sulfate level is associated with prolonged QTc interval in early CKD patients. PLoS One 2015; 10: e0119545 doi: 10.1371/journal.pone.0119545 PMID: 25893644
7. Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, Laurenzana EM, et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010; 49:393–400. doi:10.1021/bi901786x PMID: 2000589
8. Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, Strobl H. Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol 2009; 183:66–74. doi:10.4049/jimmunol.0802997 PMID: 19535631
9. Gasiewicz TA, Singh KP, Casado FL. The aryl hydrocarbon receptor has an important role in the regulation of hematopoiesis: implications for benzene-induced hematopoietic toxicity. Chem Biol Interact 2010; 184:246–251. doi: 10.1016/j.cbi.2009.10.019 PMID: 19896476
10. Miao W, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor- xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 2005; 280:20340–20348. PMID: 15790560
11. Medjakovic S, Mueller M, Jungbauer A. Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR. Nutrients 2010; 2:241–279. doi: 10.3390/nu2030241 PMID: 22254019
12. Polvani S, Tarocchi M, Galli A. PPARy and Oxidative Stress: Conβ) Catenating NRF2 and FOXO. PPAR Res 2012; 2012:641087. doi: 10.1155/2012/641087 PMID: 22481913
13. Amoruso A, Bardelli C, Gunella G, Fresno LG, Ferrero V, Brunelleschi S. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 2007; 81:906–915. PMID: 17765929
14. Ito S, Higuchi Y, Yagi Y, Nishijima F, Yamato H, Ishii H, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013; 93:837–845. doi: 10.1189/jlb.0112023 PMID: 23362306
15. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 2013; 84:733–744. doi: 10.1038/ki.2013.133 PMID: 23636172
16. Rateri DL, Howatt DA, Moorschagen JJ, Charnigo R, Cassis LA, Daugherty A. Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol 2011; 179:1542–1548. doi: 10.1016/j.ajpath.2011.05.049 PMID: 21763672
17. Kaneko H, Anzai T, Takahashi T, Kohn T, Shimoda M, Sasaki A, et al. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res 2011; 91:358–67. doi: 10.1093/cvr/cvr080 PMID: 21436157

18. Ghigliotti G, Barisione C, Garibaldi S, Brunelli C, Palmieri D, Spinella G, et al. CD16(+) monocyte subsets are increased in large abdominal aortic aneurysms and are differentially related with circulating and cell-associated biochemical and inflammatory biomarkers. Dis Markers 2013; 34:131–142. PMID: 23348634

19. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol 2009; 174:1097–1108. doi: 10.2353/ajpath.2009.080431 PMID: 19234137

20. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56:486–95. doi: 10.1053/j.ajkd.2010.03.026 PMID: 20557989

21. Barisione C, Garibaldi S, Ghigliotti G, Fabbi P, Altieri P, Casale MC, et al. CD14CD16 monocyte subset levels in heart failure patients. Dis Markers 2010; 28:115–124. doi: 10.3233/DMA-2010-0691 PMID: 20364047

22. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 2011; 25:191–197. doi: 10.1002/jcla.20456 PMID: 21567467

23. Urbani S, Caporale R, Lombardini L, Bosi A, Saccardi R. Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytometry 2006; 8:243–253. PMID: 16793733

24. Majkova Z, Smart E, Toborek M, Hennig B. Up-regulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent. Toxicol Appl Pharmacol 2009; 237:1–7. doi: 10.1016/j.taap.2009.02.016 PMID: 19265715

25. Phillips RJ, Lutz M, Premack B. Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation. J Inflamm (Lond) 2005; 31:2–14.

26. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J Biol Chem 2010; 285:24388–97.

27. Majkova Z, Smart E, Toborek M, Hennig B. Up-regulation of endothelial monocyte chemoattractant protein-1 by coplanar PCB77 is caveolin-1-dependent. Toxicol Appl Pharmacol 2009; 237:1–7. doi: 10.1016/j.taap.2009.02.016 PMID: 19265715

28. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32:84–92. doi: 10.1093/eurheartj/ehq371 PMID: 20943670

29. Merino A, Buendia P, Martin-Malo A, Alajama P, Ramirez R, Carracedo J. Senescent CD14+CD16+ monocytes exhibit proinflammatory and proatherosclerotic activity. J Immunol 2011; 186:1809–1815. doi: 10.4049/jimmunol.1001866 PMID: 2191073

30. Pollfiet MM, Fabriek BO, Daniëls WP, Dijkstra CD, van den Berg TK. The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology 2006; 211:419–425. PMID: 16920481

31. Boyle JJ, Johns M, Lo J, Chiodini A, Ambrose N, Evans PC, et al. Heme induces hemeoxygenase 1 via Nrf2: role in the homeostatic macrophage response to intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2011; 31:2865–2869. doi: 10.1161/ATVBAHA.111.225813 PMID: 21886703

32. Ugoccia P, Barlase S, Dada A, Schmitz G. Regulation of surface CD163 expression and cellular effects of receptor mediated hemoglobin-haptoglobin uptake on human monocytes and macrophages. Cytometry A 2006; 69:203–205. PMID: 16479607

33. Lin CJ, Pan CF, Liu HL, Chuang CK, Jayakumar T, Wang TJ, et al. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. Atherosclerosis 2012; 225:173–8. doi: 10.1016/j.atherosclerosis.2012.07.012 PMID: 22981405

34. Adesso S, Popolo A, Bianco G, Sorrentino R, Pinto A, Autore G, et al. The uremic toxin indoxyl sulphate enhances macrophage response to LPS. PLoS One 2013; 30:e76778.

35. Bolati D, Shimizu H, Yisireylı M, Nishijima F, Niwa T. Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-κB. BMC Nephrol 2013; 4:14-56.

36. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J 2013; 77:224–230. PMID: 23037589
37. Arsenescu V, Arsenescu R I, King V, Swanson H, Cassis LA. Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Environ Health Perspect 2008; 116:761–768. doi:10.1289/ehp.10554 PMID: 18560532

38. Arsenescu R, Arsenescu V, Zhong J, Nasser M, Melinte R, Dingle RW, et al. Role of the xenobiotic receptor in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1149–1162. doi:10.1002/ibd.21463 PMID: 20878756

39. Evans BR, Karchner SI, Allan LL, Pollenz RS, Tanguay RL, Jenny MJ, et al. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. Mol Pharmacol 2008; 73:387–98. PMID:18000031

40. Figarola JL, Weng Y, Lincoln C, Horne D, Rahbar S. Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis. Invest New Drugs 2012; 30:1413–1425. doi:10.1007/s10637-011-9711-8 PMID: 21728022

41. Ullevig S, Zhao Q, Lee CF, Seok Kim H, Zamora D, Asmis R. NADPH oxidase 4 mediates monocyte priming and accelerated chemotaxis induced by metabolic stress. Arterioscler Thromb Vasc Biol 2012; 32:415–26. doi:10.1161/ATVBAHA.111.238899 PMID: 22095986

42. Shantsila E, Tapp LD, Wrigley BJ, Pamukcu B, Apostolakis S, Montoro-García S, et al. Monocyte subsets in coronary artery disease and their associations with markers of inflammation and fibrinolysis. Atherosclerosis 2014; 234:4–10. doi:10.1016/j.atherosclerosis.2014.02.009 PMID: 24583499

43. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6:137–143. PMID: 17681149

44. Byström J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008; 112:4117–4127. doi:10.1182/blood-2007-12-129767 PMID: 18779392

45. Takada Y, Hisamatsu T, Kamada N, Kitazume MT, Honda H, Oshima Y, et al. Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol 2010; 184:2671–2676. doi:10.4049/jimmunol.0804012 PMID: 20107182

46. Bähr IN, Tretter P, Krüger J, Stark RG, Schimkus J, Unger T, et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypertension 2011; 58:725–732. doi:10.1161/HYPERTENSIONAHA.111.173542 PMID: 21867071

47. Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 2008; 112:4117–4127. doi:10.1182/blood-2007-12-129767 PMID: 18779392

48. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Györi G, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 2007; 31:1420–1428.

49. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 2009; 27:1333–40. doi:10.1097/HJH.0b013e328329bbf4 PMID: 19365285

50. Virzi GM, de Cal M, Day S, Brocca A, Cruz DN, Castellani C, et al. Pro-Apoptotic Effects of Plasma from Patients with Cardiorenal Syndrome on Human Tubular Cells. Am J Physiol Lung Cell Mol Physiol 2011; 300:341–383.

51. Dawson J, Cockenill G, Choke E, Thompson MM. Aortic aneurysms as a source of circulating interleukin-6. Ann N Y Acad Sci 2006; 1085:320–3 PMID: 17182950

52. Azizzadeh A, Sanchez LA, Miller CC 3rd, Marine L, Rubin BG, Safi HJ, et al. Glomerular filtration rate is a predictor of mortality after endovascular abdominal aortic aneurysm repair. J Vasc Surg 2006; 43:14–8 PMID: 16414381

53. Wang M, Spinetti G, Monticone RE, Zhang J, Wu J, Jiang L, et al. A local proinflammatory signalling loop facilitates adverse age-associated arterial remodeling. PLoS One 2011; 6:e16653 doi:10.1371/journal.pone.0016653 PMID: 21347430

54. Vianez L, Annaert P, de Loor H, Poensen R, Evenepoel P, Meijers B. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. Biopharm Drug Dispos 2013; 34:165–75. doi: 10.1002/bdd.1834 PMID: 23300093